Medtronic plc.NYSE: MDT

Medtronic receives CE Mark for next-generation portfolio of pacemakers engineered for conduction system pacing

· Issued by Medtronic plc.

Summary by 6ix AI

Medtronic plc said on October 19, 2026 that its Vitalis portfolio of pacemakers has received CE Mark, a European regulatory marking for medical devices. Medtronic is a healthcare technology company.

Key details

  • The portfolio includes five pacemakers: ReSyncra CSP, Restoria CSP, Refina CSP, Effectra and Confirma.
  • Medtronic says the pacemakers offer a range of pacing options with features built for conduction system pacing (CSP), a therapy that paces the heart through its own electrical conduction pathways.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/medtronic-receives-ce-mark-for-next-generation-portfolio-of-pacemakers-engineered-for-conduction-system-pacing

Watch Medtronic's latest callMedtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call · Replay · Sep 1Read the transcript of Medtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call
GALWAY, Ireland - October 19 - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Vitalis™ portfolio of cardiac devices - ReSyncra CSP™, Restoria CSP™, Refina CSP™, Effectra™, and Confirma™ pacemakers - has received CE Mark. Together, these pacemakers offer a comprehensive suite of pacing options that include advanced features purpose-built for conduction system pacing (CSP) therapy. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Medtronic plc. on 6ix

Story so far

Earlier from Medtronic

Later from Medtronic

All Medtronic news releases